Exclusive Summary

• • Potential FIC, A clinically unvalidated target, with no clinical competitors yet.
• • Significantly superior in vitro and in vivo anti-tumor efficacy comapre with M3913.
• • Favorable PK and safety profile in pre-clinical studies.